Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.690
+0.150 (9.74%)
Dec 20, 2024, 4:00 PM EST - Market closed
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 9.43, with a low estimate of 5.00 and a high estimate of 13. The average target predicts an increase of 457.99% from the current stock price of 1.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 → $5 | Strong Buy | Reiterates | $7 → $5 | +195.86% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $10 → $8 | Buy | Reiterates | $10 → $8 | +373.37% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $10 | Buy | Maintains | $7 → $10 | +491.72% | Nov 21, 2024 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +314.20% | Nov 21, 2024 |
Financial Forecast
Revenue This Year
14.10M
Revenue Next Year
n/a
from 14.10M
EPS This Year
-1.11
from -1.85
EPS Next Year
-1.24
from -1.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 17.0M | n/a | 26.3M | |||
| Avg | 14.1M | n/a | 8.5M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.05 | -0.81 | -0.84 | |||
| Avg | -1.11 | -1.24 | -1.27 | |||
| Low | -1.35 | -1.43 | -1.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.